Mixed Meal and Intravenous L-Arginine Tests Both Stimulate Incretin Release Across Glucose Tolerance in Man: Lack of Correlation with β Cell Function.

@article{Ruetten2018MixedMA,
  title={Mixed Meal and Intravenous L-Arginine Tests Both Stimulate Incretin Release Across Glucose Tolerance in Man: Lack of Correlation with $\beta$ Cell Function.},
  author={Hartmut Ruetten and Mathias Gebauer and Ralph H. Raymond and Roberto A Calle and Claudio Cobelli and Atalanta Ghosh and R. Paul Robertson and Sudha S Shankar and Myrlene A Staten and Darko Stefanovski and Adrian Vella and Kathryn Wright and David A. Fryburg},
  journal={Metabolic syndrome and related disorders},
  year={2018},
  volume={16 8},
  pages={
          406-415
        }
}
BACKGROUND The aims of this study were to 1. define the responses of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), glucagon, and peptide YY (PYY) to an oral meal and to intravenous L-arginine; and 2. examine correlation of enteroendocrine hormones with insulin secretion. We hypothesized a relationship between circulating incretin concentrations and insulin secretion. METHODS Subjects with normal glucose tolerance (NGT, n = 23), prediabetes (PDM, n = 17… Expand
2 Citations
Effects of mixed meal tolerance test on gastric emptying, glucose and lipid homeostasis in obese nonhuman primates
TLDR
It is demonstrated that mixed meal administration induces significant secretion of several incretins which are critical for maintaining glucose homeostasis and reproducible in NHPs, which is important when the MMTT is used for evaluating post-meal glucoseHomeostasis in research. Expand
Stimulus-Secretion Coupling in Beta-Cells: From Basic to Bedside.
  • M. Islam
  • Medicine, Chemistry
  • Advances in experimental medicine and biology
  • 2020
TLDR
A better understanding of the stimulus-secretion coupling may lead to the discovery of other molecular targets for development of drugs for the prevention and treatment of type 2 diabetes. Expand

References

SHOWING 1-10 OF 24 REFERENCES
The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.
TLDR
GLP-1 increases insulin secretion in patients with type 2 diabetes and control subjects in a dose-dependent manner and that the beta-cell responsiveness to glucose may be increased to normal levels with a low dose of GLP- 1 infusion. Expand
Oral L-arginine stimulates GLP-1 secretion to improve glucose tolerance in male mice.
TLDR
The hypothesis that oral L-arginine acts as a GLP-1 secretagogue in vivo, to augment postprandial insulin secretion and improve glucose tolerance is tested and the intriguing possibility that L- arginine-based nutritional and/or pharmaceutical therapies may benefit glucose tolerance by improving the postpr andial GLP1 response in obese individuals is raised. Expand
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
TLDR
Factors are identified that may determine individual incretin secretory responses and explain some of the variations in published findings of group differences in GLP-1 responses to nutrient intake that do not support the contention of a generalised defect in nutrient-related GLp-1secretory responses in type 2 diabetes patients. Expand
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
TLDR
In mild type-2 diabetes, GLP-1 [7-36 amide], in contrast to GIP, retains much of its insulinotropic activity and lowers glucagon concentrations. Expand
Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action
TLDR
It is proposed that differentiated preventive initiatives in prediabetic individuals should be tested, targeting the specific underlying metabolic defects. Expand
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.
TLDR
It is concluded that the meal-related glucagon-like peptide-1 response in type 1 diabetes is decreased, which may contribute to the decreased incretin effect in type 2 diabetes. Expand
Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study
TLDR
The primary mechanism leading to hyperglycaemia in participants with isolated IFG is likely to be impaired basal and first-phase insulin secretion, whereas in isolated IGT the primary mechanismLeading to postglucose load hyper glycaemia is insulin resistance. Expand
Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of β-Cell Function: Results From the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series
TLDR
Standardized MMTT and AST provide reproducible and complementary measures of BCF with characteristics favorable for longitudinal interventional trials use. Expand
Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes
TLDR
Near-normalisation of blood glucose for 4 weeks improves beta cell responsiveness to both GLP-1 and GIP by a factor of three to four, and no effect was found on betacell responsiveness to glucose alone. Expand
Defects in GLP-1 response to an oral challenge do not play a significant role in the pathogenesis of prediabetes.
TLDR
The lack of association of GLP-1 concentrations with glucose tolerance status and with insulin secretion and action in a cohort encompassing the full spectrum of prediabetes strongly argues against a significant contribution of defects in GLP -1 secretion to the pathogenesis ofprediabetes. Expand
...
1
2
3
...